{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:18:09Z","timestamp":1791487089094,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-16059-5","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T16:12:15Z","timestamp":1756224735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combining serologic biomarkers with the PAGE B score improves risk stratification for hepatocellular carcinoma development among chronic hepatitis B patients"],"prefix":"10.1038","volume":"15","author":[{"given":"Michael","family":"Stec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Fortney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny Ka-Ho","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lung-Yi","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin A.","family":"Cloherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"issue":"6","key":"16059_CR1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay, H. et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J. Hepatol. 77 (6), 1598\u20131606 (2022).","journal-title":"J. Hepatol."},{"issue":"4","key":"16059_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1055\/s-0034-1394365","volume":"34","author":"V Mazzaferro","year":"2014","unstructured":"Mazzaferro, V., Lencioni, R. & Majno, P. Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation. Semin. Liver Dis. 34 (4), 415\u2013426 (2014).","journal-title":"Semin. Liver Dis."},{"key":"16059_CR3","doi-asserted-by":"crossref","unstructured":"Zahid, M. N. Transplantation of organs from hepatitis C Virus-Positive donors under Direct-Acting antiviral regimens. J. Clin. Med.  11(3). (2022).","DOI":"10.3390\/jcm11030770"},{"issue":"9","key":"16059_CR4","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.2008.20.7753","volume":"27","author":"SF Altekruse","year":"2009","unstructured":"Altekruse, S. F., McGlynn, K. A. & Reichman, M. E. Hepatocellular carcinoma incidence, mortality, and survival trends in the united States from 1975 to 2005. J. Clin. Oncol. 27 (9), 1485\u20131491 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"16059_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/MCG.0b013e318224d669","volume":"46","author":"JA Davila","year":"2012","unstructured":"Davila, J. A., Duan, Z., McGlynn, K. A. & El-Serag, H. B. Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the united States. J. Clin. Gastroenterol. 46 (1), 71\u201377 (2012).","journal-title":"J. Clin. Gastroenterol."},{"key":"16059_CR6","doi-asserted-by":"crossref","unstructured":"Bockmann, J. H. et al. High rates of liver cirrhosis and hepatocellular carcinoma in chronic hepatitis B patients with metabolic and cardiovascular comorbidities. Microorganisms. 9(5). (2021).","DOI":"10.3390\/microorganisms9050968"},{"issue":"2","key":"16059_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.21037\/jgo.2017.03.14","volume":"8","author":"PJ Zamor","year":"2017","unstructured":"Zamor, P. J., deLemos, A. S. & Russo, M. W. Viral hepatitis and hepatocellular carcinoma: etiology and management. J. Gastrointest. Oncol. 8 (2), 229\u2013242 (2017).","journal-title":"J. Gastrointest. Oncol."},{"issue":"6","key":"16059_CR8","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","volume":"142","author":"HB El-Serag","year":"2012","unstructured":"El-Serag, H. B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 142 (6), 1264\u201373e1 (2012).","journal-title":"Gastroenterology"},{"issue":"3","key":"16059_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1440-1746.2009.05784.x","volume":"24","author":"MF Yuen","year":"2009","unstructured":"Yuen, M. F., Hou, J. L. & Chutaputti, A. Hepatocellular carcinoma in the Asia Pacific region. J. Gastroenterol. Hepatol. 24 (3), 346\u2013353 (2009).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"16059_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2017.0112","volume":"24","author":"BH Kim","year":"2018","unstructured":"Kim, B. H. & Park, J. W. Epidemiology of liver cancer in South Korea. Clin. Mol. Hepatol. 24 (1), 1\u20139 (2018).","journal-title":"Clin. Mol. Hepatol."},{"key":"16059_CR11","doi-asserted-by":"crossref","unstructured":"Pavlovic, N., Rani, B., Gerwins, P. & Heindryckx, F. Platelets as key factors in hepatocellular carcinoma. Cancers (Basel).  11(7). (2019).","DOI":"10.3390\/cancers11071022"},{"issue":"13","key":"16059_CR12","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1002\/cncr.31406","volume":"124","author":"SW Yi","year":"2018","unstructured":"Yi, S. W., Choi, J. S., Yi, J. J., Lee, Y. H. & Han, K. J. Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: A prospective cohort study in Korea. Cancer. 124 (13), 2748\u20132757 (2018).","journal-title":"Cancer"},{"key":"16059_CR13","doi-asserted-by":"crossref","unstructured":"Nevola, R. et al. Gender differences in the pathogenesis and risk factors of hepatocellular carcinoma. Biology (Basel). 12(7). (2023).","DOI":"10.3390\/biology12070984"},{"issue":"4","key":"16059_CR14","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","volume":"64","author":"G Papatheodoridis","year":"2016","unstructured":"Papatheodoridis, G. et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J. Hepatol. 64 (4), 800\u2013806 (2016).","journal-title":"J. Hepatol."},{"issue":"3","key":"16059_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3350\/cmh.2016.0045","volume":"22","author":"I Varbobitis","year":"2016","unstructured":"Varbobitis, I. & Papatheodoridis, G. V. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. Clin. Mol. Hepatol. 22 (3), 319\u2013326 (2016).","journal-title":"Clin. Mol. Hepatol."},{"issue":"12","key":"16059_CR16","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/liv.13450","volume":"37","author":"MN Kim","year":"2017","unstructured":"Kim, M. N. et al. Validation of PAGE-B model in Asian chronic hepatitis B patients receiving Entecavir or Tenofovir. Liver Int. 37 (12), 1788\u20131795 (2017).","journal-title":"Liver Int."},{"issue":"5","key":"16059_CR17","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.jhep.2022.12.029","volume":"78","author":"B Surial","year":"2023","unstructured":"Surial, B. et al. External validation of the PAGE-B score for HCC risk prediction in people living with HIV\/HBV coinfection. J. Hepatol. 78 (5), 947\u2013957 (2023).","journal-title":"J. Hepatol."},{"issue":"9","key":"16059_CR18","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1111\/liv.14129","volume":"39","author":"HW Lee","year":"2019","unstructured":"Lee, H. W. et al. External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. Liver Int. 39 (9), 1624\u20131630 (2019).","journal-title":"Liver Int."},{"issue":"2","key":"16059_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jhep.2021.09.025","volume":"76","author":"HY Kim","year":"2022","unstructured":"Kim, H. Y. et al. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. J. Hepatol. 76 (2), 311\u2013318 (2022).","journal-title":"J. Hepatol."},{"key":"16059_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.reth.2021.03.002","volume":"17","author":"T Yamashita","year":"2021","unstructured":"Yamashita, T. & Kaneko, S. Liver cancer stem cells: recent progress in basic and clinical research. Regen. Ther. 17, 34\u201337 (2021).","journal-title":"Regen. Ther."},{"issue":"3","key":"16059_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.5582\/ddt.2014.01026","volume":"8","author":"K Zhang","year":"2014","unstructured":"Zhang, K. et al. Perspectives on a combined test of multi serum biomarkers in china: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Drug Discov. Ther. 8 (3), 102\u2013109 (2014).","journal-title":"Drug Discov. Ther."},{"issue":"2","key":"16059_CR22","doi-asserted-by":"publisher","first-page":"e0228857","DOI":"10.1371\/journal.pone.0228857","volume":"15","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One. 15 (2), e0228857 (2020).","journal-title":"PLoS One"},{"issue":"12","key":"16059_CR23","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/01.OGX.0000099770.97668.18","volume":"58","author":"GJ Mizejewski","year":"2003","unstructured":"Mizejewski, G. J. Levels of alpha-fetoprotein during pregnancy and early infancy in normal and disease States. Obstet. Gynecol. Surv. 58 (12), 804\u2013826 (2003).","journal-title":"Obstet. Gynecol. Surv."},{"issue":"1","key":"16059_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000217540","volume":"9","author":"J Breborowicz","year":"2009","unstructured":"Breborowicz, J. Microheterogeneity of human alphafetoprotein. Tumor Biol. 9 (1), 3\u201314 (2009).","journal-title":"Tumor Biol."},{"issue":"7","key":"16059_CR25","doi-asserted-by":"publisher","first-page":"e28806","DOI":"10.5812\/hepatmon.28806v2","volume":"15","author":"R Yu","year":"2015","unstructured":"Yu, R. et al. Performance of protein induced by vitamin K absence or Antagonist-II (PIVKA-II) for hepatocellular carcinoma screening in Chinese population. Hepat. Mon. 15 (7), e28806 (2015).","journal-title":"Hepat. Mon"},{"issue":"6","key":"16059_CR26","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1080\/00365521.2018.1459824","volume":"53","author":"GP Caviglia","year":"2018","unstructured":"Caviglia, G. P. et al. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis. Scand. J. Gastroenterol. 53 (6), 734\u2013740 (2018).","journal-title":"Scand. J. Gastroenterol."},{"issue":"2","key":"16059_CR27","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/hep.31758","volume":"74","author":"T Yamashita","year":"2021","unstructured":"Yamashita, T. et al. Serum laminin \u03b32 monomer as a diagnostic and predictive biomarker for hepatocellular carcinoma. Hepatology 74 (2), 760\u2013775 (2021).","journal-title":"Hepatology"},{"issue":"1","key":"16059_CR28","doi-asserted-by":"publisher","first-page":"25395","DOI":"10.1038\/s41598-024-77068-4","volume":"14","author":"K Nio","year":"2024","unstructured":"Nio, K. et al. Serum laminin \u03b32 monomer as a predictive biomarker for hepatocellular carcinoma in patients with chronic hepatitis B virus infection: a retrospective cohort study. Sci. Rep. 14 (1), 25395 (2024).","journal-title":"Sci. Rep."},{"issue":"12","key":"16059_CR29","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","volume":"5","author":"C-H Tseng","year":"2020","unstructured":"Tseng, C-H. et al. Hepatocellular carcinoma incidence with Tenofovir versus Entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 5 (12), 1039\u20131052 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"16059_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12014-023-09444-7","volume":"20","author":"PM Hemken","year":"2023","unstructured":"Hemken, P. M. et al. Validation of the novel GLAS algorithm as an aid in the detection of liver fibrosis and cirrhosis based on GP73, LG2m, age, and sex. Clin. Proteom. 20 (1), 53 (2023).","journal-title":"Clin. Proteom."},{"issue":"39","key":"16059_CR31","doi-asserted-by":"publisher","first-page":"e30936","DOI":"10.1097\/MD.0000000000030936","volume":"101","author":"TY Jang","year":"2022","unstructured":"Jang, T. Y. & Dai, C. Y. Cutoff values of protein induced by vitamin K absence or antagonist II for diagnosing hepatocellular carcinoma. Med. (Baltim). 101 (39), e30936 (2022).","journal-title":"Med. (Baltim)."},{"issue":"3","key":"16059_CR32","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J. Hepatol. 76 (3), 681\u2013693 (2022).","journal-title":"J. Hepatol."},{"issue":"4","key":"16059_CR33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/00365513.2017.1303190","volume":"77","author":"S Dahlberg","year":"2017","unstructured":"Dahlberg, S., Nilsson, C. U., Kander, T. & Sch\u00f6tt, U. Detection of subclinical vitamin K deficiency in neurosurgery with PIVKA-II. Scand. J. Clin. Lab. Investig. 77 (4), 267\u2013274 (2017).","journal-title":"Scand. J. Clin. Lab. Investig."},{"issue":"5","key":"16059_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1872-034X.2011.00785.x","volume":"41","author":"H Kobashi","year":"2011","unstructured":"Kobashi, H. et al. Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with Entecavir or lamivudine. Hepatol. Res. 41 (5), 405\u2013416 (2011).","journal-title":"Hepatol. Res."},{"issue":"3","key":"16059_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.5152\/dir.2014.13370","volume":"20","author":"H Arif-Tiwari","year":"2014","unstructured":"Arif-Tiwari, H. et al. MRI of hepatocellular carcinoma: an update of current practices. Diagn. Interv. Radiol. 20 (3), 209\u2013221 (2014).","journal-title":"Diagn. Interv. Radiol."},{"issue":"12","key":"16059_CR36","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.4254\/wjh.v7.i12.1632","volume":"7","author":"MH Attwa","year":"2015","unstructured":"Attwa, M. H. & El-Etreby, S. A. Guide for diagnosis and treatment of hepatocellular carcinoma. World J. Hepatol. 7 (12), 1632\u20131651 (2015).","journal-title":"World J. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16059-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16059-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16059-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T03:18:21Z","timestamp":1757474301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16059-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["16059"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-16059-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conflicts of Interest and Source of Funding: MS, MA, MR, TF, and GC are employees and shareholders of Abbott Laboratories. All other authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31471"}}